21
Apr

Demonstrating once again that gene therapy research has emerged as one of the hottest fields in biotech, Cambridge, MA-based Dimension Therapeutics has rounded up a $65 million B round from a slate of new and existing investors. Adding in Bayer’s $20 million upfront for signing on as a partner last summer along with its A round, Dimension has now banked more than $100 million for its R&D activities. The only question now is whether it will wait long to file an IPO.

…read more

Source: Gene therapy player Dimension stirs IPO buzz with $65M venture round

    

0 No comments